## **Core Concept**
Bevacizumab is a recombinant humanized monoclonal antibody that targets **vascular endothelial growth factor A (VEGF-A)**, preventing its interaction with VEGF receptors on endothelial cells. This action inhibits angiogenesis, which is crucial for tumor growth and metastasis. Bevacizumab is primarily used in the treatment of various cancers.

## **Why the Correct Answer is Right**
Bevacizumab works by binding to VEGF-A, a protein that stimulates the formation of blood vessels. Tumors need a blood supply to grow beyond a certain size, a process known as angiogenesis. By inhibiting VEGF-A, bevacizumab effectively cuts off the tumor's blood supply, slowing its growth. This mechanism is particularly beneficial in cancers known to have high levels of VEGF-A.

## **Why Each Wrong Option is Incorrect**
- **Option A:** While bevacizumab's mechanism involves blocking angiogenesis, option A is not specified. Generally, bevacizumab is not primarily associated with diseases or conditions not listed.
- **Option B:** Similarly, without specifics, it's hard to directly refute, but bevacizumab's primary use is well-documented in certain cancers.
- **Option C:** This option might seem plausible if it relates to a condition or disease where bevacizumab isn't primarily indicated.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that bevacizumab is notably used in the treatment of **colorectal cancer**, **breast cancer**, **lung cancer**, and **renal cell carcinoma**. A classic association is its use in metastatic colorectal cancer in combination with chemotherapy. A potential side effect to recall is the increased risk of **hypertension** and **proteinuria**.

## **Correct Answer:** . Colorectal cancer